- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01093079
Laparoscopic Versus Open Partial Nephrectomy - Surgical and Oncological Outcomes (LapVsOpen prtn)
March 24, 2010 updated by: Rabin Medical Center
Partial Nephrectomy is the standard care for small (<4 cm) renal tumors.
Despite the expanding use of laparoscopic approach, debate exist regarding the short and long term outcomes compared to the open approach.
Our goal is to perform a prospective randomized trial to compare these methods
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Petach Tikva, Israel
- Recruiting
- Rabin Medical Center
-
Contact:
- shay golan, MD
- Phone Number: 972-50-3447573
- Email: shaygo1@yahoo.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients referred to partial nephrectomy due to renal lesion , suspected to be a tumor
Description
Inclusion Criteria:
- patients referred to partial nephrectomy
Exclusion Criteria:
- Contra-indication for laparocopic surgery
- Complexed , large tumors, single kidney, chronic renal failure
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Laparoscopic partial nephrectomy
|
Laparoscopic partial nephrectomy
|
|
Open Partial nephrectomy
|
Open partial nephrectomy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion
December 7, 2022
Study Completion
December 7, 2022
Study Registration Dates
First Submitted
March 24, 2010
First Submitted That Met QC Criteria
March 24, 2010
First Posted (Estimate)
March 25, 2010
Study Record Updates
Last Update Posted (Estimate)
March 25, 2010
Last Update Submitted That Met QC Criteria
March 24, 2010
Last Verified
July 1, 2009
More Information
Terms related to this study
Other Study ID Numbers
- 5489
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tumor
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Avelos Therapeutics Inc.RecruitingSolid Tumor | Solid Tumor Cancer | Solid Tumor, Adult | Solid Tumor, Unspecified, Adult | Tumor, Solid | Solid Tumor in Advanced Stage | Solid Tumors Refractory to Standard TherapyKorea, Republic of
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyActive, not recruitingPD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation TumorKorea, Republic of
-
Monopar TherapeuticsAvailableCancer | Solid Tumor | Solid Tumor Cancer | Oncology | uPAR-positive Solid Tumor | Urokinase Plasminogen Activator Receptor-positive Solid TumorUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Australia, Taiwan, United States
Clinical Trials on Laparoscopic partial nephrectomy
-
South Valley UniversityCompletedPartial Nephrectomy | Laparoscopic | Renal Tumors | PentafectaEgypt
-
Menoufia UniversityRecruiting
-
Samsun Liv HospitalOndokuz Mayıs UniversityCompletedKidney Neoplasms | Urologic Neoplasms | Renal Cell Carcinoma | Surgery | Kidney Injury | Renal Cancer | Oncology | Urologic Cancer | Renal Neoplasm | Kidney IschemiaTurkey
-
South Valley UniversityCompletedTrifecta Achievement | Pentafecta AchievementEgypt
-
Sohag UniversityNot yet recruiting
-
GCS Ramsay Santé pour l'Enseignement et la RechercheEuraxi PharmaRecruiting
-
Samsung Medical CenterUnknownRenal Cell CarcinomaKorea, Republic of
-
RenJi HospitalNational Natural Science Foundation of ChinaCompleted
-
St. Petersburg State Pavlov Medical UniversitySaint Petersburg State University, RussiaCompleted
-
Xuanwu Hospital, BeijingUnknownRenal Cell CarcinomaChina